|
COPYRIGHT 2003 International Medical News Group
MAUI, HAWAII -- Patients with primary nodular cutaneous amyloidosis can be reassured that progression to systemic amyloidosis is uncommon, Dr. John S. Walsh said at the annual Hawaii dermatology seminar sponsored by the Skin Disease Education Foundation.
That's good news, because systemic amyloidosis is a disease with a notoriously poor prognosis, with a median survival of just 1-2 years, observed Dr. Walsh of the Mayo Clinic, Jacksonville, Fla.
He presented a retrospective study of 16 patients diagnosed with nodular amyloidosis...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
